The benefits of cilostazol on claudicant patients with prior aortoiliac or femoropopliteal revascularization is previously described, but the literature preoperative use this medication in chronic limb-threatening ischemia (CLTI) limited. We hypothesized that undergoing intervention for CLTI would have reduced perioperative amputations, and improved long-term survival. Vascular Quality Initiati...

Purpose: The aim of this study is to examine the potential effect cilostazol and inflammation on cognitive impairment after stroke in an Asian population. Methods: Forty-five patients with ischemic using were enrolled as group 45 aspirin or clopidogrel control group. Neuropsychiatric assessments administered at start 6 months. Multiple logistic regression analysis was used estimate association ...

BACKGROUND AND PURPOSE White-matter (WM) lesions are known to potentiate cognitive impairment in poststroke patients. The present study was designed to assess whether Ginkgo biloba extract (GB) and cilostazol, which were evaluated alone and in a combination formula (Renexin), can attenuate the WM lesions and cognitive decline caused by chronic hypoperfusion in the rat. METHODS ANIMALS WERE DI...

BACKGROUND Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator. This prospective, randomized, placebo-controlled, parallel-group clinical trial evaluated the efficacy of cilostazol for treatment of stable, moderately severe intermittent claudication. METHODS AND RESULTS Study inclusion criteria included age > or =...

OBJECTIVE Ionic remodeling has a close correlation with the occurrence of atrial fibrillation (AF). Atrial tachypacing remodeling is associated with characteristic ionic remodeling. The purpose of this study was to assess the efficacy of cilostazol, an oral phosphodiesterase 3 inhibitor, for preventing atrial ionic remodeling in long-term rapid atrial pacing (RAP) dogs. METHODS We use the met...

GOAL Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly. We investigated whether the phosphodiesterase III inhibitor cilostazol, which is often used in the prevention of stroke and peripheral artery disease, may delay cognitive decline in the eld...

Cilostazol (OPC-13013; 6-[4-(1-cyclohexl-1H-tetrazol-5-yl)butoxy]3,4-dihydro-2(1H)-quinolinone) is widely used as an antiplatelet vasodilator agent. In vitro, the hydroxylation of the quinone moiety of cilostazol to OPC-13326 [6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-4-hydroxy-2(1H)-quinolinone], is the predominant route, and the hydroxylation of the hexane moiety to OPC-13217 is...

Elevation of cAMP in platelets is recognized to play a suppressive role in platelet functions. We have previously shown that adenosine diphosphate (ADP)-induced phosphorylation of heat shock protein 27 (HSP27) via p38 mitogen-activated protein (MAP) kinase is correlated with platelet-derived growth factor (PDGF)-AB secretion and soluble CD40 ligand (sCD40L) release. In the present study, we inv...

Although prior studies have shown the short-term benefits of cilostazol on claudicant patients who underwent iliac or femoropopliteal revascularization procedures, literature with chronic limb ischemia (CLI) is limited. Recent molecular analysis suggests that possible cardiovascular are mediated through a nitric oxide pathway. As such, we hypothesized use in undergoing intervention for CLI woul...

BACKGROUND Aspirin is widely used for secondary prevention after stroke. Cilostazol has shown promise as an alternative to aspirin in Asian people with stroke. OBJECTIVES To determine the relative effectiveness and safety of cilostazol compared directly with aspirin in the prevention of stroke and other serious vascular events in patients at high vascular risk for subsequent stroke, those wit...